 |
|
|
 |
|
Obesity, Insulin Level Impact Prostate Cancer Survival
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 Overweight men (those with a BMI of 25 to 29) had a 47 percent higher risk of dying from prostate cancer, while obese men (BMI of 30 or over) were more than two-and-a-half times more likely to die of the disease, compared with men of healthy weight (BMI under 25).
Men with the highest C-peptide concentrations also had more than double the risk of dying from their cancer compared with men with the lowest levels, the study found.
Finally, men who had a BMI of more than 25 and high C-peptide concentrations had quadruple the risk of dying from their cancer compared with men who had lower BMIs and lower C-peptide levels, the researchers reported.
Text Continues Below

"This suggests that there may be a whole new story to tell, whereby not just androgens have something to do with cancer behavior, but also insulin," Pollak said.
The insulin hormone may be latching onto insulin receptors located on prostate cancer cells, he speculated.
Some pharmaceutical companies are already testing drug candidates that target insulin signaling, Pollak added.
And the findings could have broader implications for other cancers, said study lead author Dr. Jing Ma, of Harvard University's Channing Laboratory.
"The simple things are still the important things. Don't drink, don't smoke, exercise, and eat well," said Dr. Ganesh Palapattu, assistant professor of urology, pathology and oncology at the University of Rochester School of Medicine. "This is yet another piece of evidence suggesting that obesity is not a good thing for many reasons."
"Obesity is the second leading cause of cancer death in this country next to tobacco," emphasized Dr. Jay Brooks, chief of hematology/oncology at Ochsner Health System in Baton Rouge, La. "Two years ago, I would never have told my patients that obesity is increasing their risk of death from cancer. Today, I do."
More information
There's more on prostate cancer at the U.S. National Cancer Institute.
Page: << Prev | 1 | 2
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 10/6/2008
|
 |
SOURCES: Michael Pollak, M.D., professor, oncology, McGill University, Montreal, Quebec, Canada; Jing Ma, M.D., Ph.D., Channing Laboratory, Harvard University, Boston; Jay Brooks, M.D., chief, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Ganesh Palapattu, M.D., assistant professor, urology, pathology and oncology, University of Rochester School of Medicine, N.Y.; Nov. 2008, The Lancet Oncology
|